Search Results for:

Valeant Pharmaceuticals et al v. Actavis Laboratories

Actavis markets a generic version of the brand-name medication Uceris. The brand-name company and the owner of its IP have sued for infringement of formulation patents that allegedly cover Uceris. The district court construed the patent claims, and under that construction Actavis’s product does not infringe. Goodwin argues in this…

Read More

GlaxoSmithKline LLC and SmithKline Beecham (Cork) Limited v. Teva Pharmaceuticals USA, Inc.

In a closely watched patent case that is especially important to pharmaceutical patent litigation, a divided panel of the Federal Circuit upheld a verdict against Teva Pharmaceuticals USA, Inc. for $235 million for inducing infringement of a method patent. The panel upheld the inducement finding even though Teva had used…

Read More

Continental Casualty Company v. Carr

The Bankruptcy Code provides courts with broad authority to channel asbestos-related tort claims against debtors and their insurers to a trust, in order to facilitate rehabilitation in bankruptcy and ensure equal treatment of claimants. In this case Goodwin litigators represent an insurer seeking to uphold a channeling injunction against post-confirmation…

Read More

Elmrock v. Citigroup

Goodwin is representing Citigroup and wholly-owned subsidiaries in commercial litigation concerning a subordinated option in a nuclear power facility.  The plaintiff (a fund controlled by Elmrock Capital) purchased a subordinated option in the residual value of Citigroup’s interest in a nuclear power facility.  Following an appraisal that left the subordinated…

Read More